Samsung Biologics Q2 2026 Earnings: Revenue Rises to KRW 1,321 Billion Amid Global Manufacturing Expansion

Samsung Biologics Q2 2026 earnings mark another quarter of steady growth for the Incheon, South Korea-based contract development and manufacturing organization (CDMO), with the company posting revenue of KRW 1,321 billion and operating profit of KRW 586 billion for the three months ended June 2026. The results, disclosed on July 23, 2026, extend a pattern of stable execution that has defined the company’s recent quarters as global biopharmaceutical clients continue to lean on its integrated development and manufacturing network to bring new therapies to market.

“We delivered another quarter of solid execution while making meaningful progress on our growth strategy,”. “Our continued investments in global operations and future capabilities are strengthening the foundation of our business and preparing us for the next phase of industry growth. As the biopharmaceutical landscape evolves, we remain committed to providing the scale, flexibility, and expertise our clients need to bring next-generation therapies to patients.”

John Rim, President and CEO of Samsung Biologics

The Samsung Biologics Q2 2026 earnings figures compare to KRW 1,014.2 billion in revenue and KRW 477.2 billion in operating profit a year earlier, representing year-over-year gains of KRW 306.7 billion and KRW 109.2 billion, respectively. EBITDA for the quarter reached KRW 698.5 billion, up from KRW 572.1 billion in the second quarter of 2025. The company attributed the quarter’s performance to stable manufacturing operations across Plants 1 through 4 and disciplined execution across ongoing client programs, rather than to any single new product launch or contract win.

For the first half of 2026, Samsung Biologics posted revenue of KRW 2,578 billion and operating profit of KRW 1,167 billion. Cumulative contract value across the company’s client base reached USD 21.6 billion, a figure the company said reflects sustained demand for its development and manufacturing services from biopharmaceutical partners worldwide. Cumulative contract value is a metric CDMOs often use to demonstrate the depth of their long-term client relationships beyond any single quarter’s reported revenue.

Learn More

Merck’s Erbitux BRAF V600E mCRC Regimen Gets EU Approval for First-Line Treatment

Samsung Biologics Q2 2026 Earnings: Manufacturing Network Expands With Rockville and Plant 5

Beyond the topline figures, the Samsung Biologics Q2 2026 earnings disclosure also detailed several initiatives tied to its long-term manufacturing footprint. Following the earlier acquisition of its Rockville manufacturing facility in Maryland, U.S., the company continued integrating the site into its global network while maintaining ongoing commercial manufacturing operations there, a process the company described as progressing alongside its existing Korea-based plants.

Plant 5 remained on track for its planned ramp-up during the quarter, with Process Performance Qualification activities gaining momentum. Process Performance Qualification, commonly referred to as PPQ, is a required regulatory step that demonstrates a manufacturing process can consistently produce product meeting quality specifications before commercial-scale production begins. Momentum on PPQ activities is typically viewed as a leading indicator that a new manufacturing plant is nearing readiness for full commercial client programs.

The company also broadened its global commercial presence with the opening of a new sales office in the Netherlands during the third quarter of 2026, a move intended to enhance client proximity and strengthen regional support across Europe. Together, the Rockville integration, Plant 5 progress, and new European office reflect a manufacturing network that now spans multiple continents.

Beyond the Samsung Biologics Q2 2026 earnings headline numbers, the company also continued to support innovation across the broader biopharmaceutical ecosystem through the Life Science Fund, a vehicle created jointly by Samsung Biologics, Samsung Bioepis, and Samsung C&T, and managed by Samsung Venture Investment. In May, the fund made an investment in Cartography Biosciences to support global collaboration in genomics-based antigen discovery and oncology drug development. The following month, the partners committed an additional KRW 200 billion to establish a third Life Science Fund, extending a multi-year commitment to early-stage biopharmaceutical innovation.

Learn More

Danaher Corporation Q2 2026 Financial Results; Strategic Capital Allocation, and Market Valuation Dynamics

Looking beyond the current quarter, Samsung Biologics said it plans to further advance its proprietary platform technologies, an effort aimed at strengthening core CDMO capabilities and expanding expertise across diverse treatment modalities as client needs continue to evolve. For a CDMO, platform technology investment is generally viewed as a way to shorten development timelines for clients working across biologics, cell and gene therapy, and other modalities.

Samsung Biologics Q2 2026 Earnings: Sustainability Recognition Reinforces ESG Commitment

Alongside the Samsung Biologics Q2 2026 earnings figures, the company highlighted continued recognition on the sustainability front. The company was included in the Dow Jones Best-in-Class Indices for the fifth consecutive year, a distinction tied to responsible business practices and ESG performance relative to industry peers. During the quarter, Samsung Biologics also published its annual ESG report, a step the company described as reinforcing transparency and stakeholder engagement across its global operations.

Looking ahead, and building on the Samsung Biologics Q2 2026 earnings performance, the company said it remains on track to achieve the upper end of its previously announced 2026 guidance. The company plans to continue executing its expansion strategy through ongoing investment in its manufacturing network, global operations, and future capabilities, positioning itself for what its CEO has characterized as the next phase of biopharmaceutical industry growth.

A central piece of that forward strategy is the recently announced all-cash public tender offer to acquire PolyPeptide Group, a transaction the company expects to complete toward the end of 2026. Samsung Biologics described the deal as another strategic step toward broadening its portfolio into peptide therapeutics, expanding its global network, and reinforcing operational resilience as market demand across the CDMO sector continues to evolve. Combined with the Rockville acquisition and Plant 5 ramp-up, the PolyPeptide deal signals a company actively diversifying beyond its traditional large-molecule biologics manufacturing base.

First-Half 2026 Financial Summary

Q2–Q3 2026 Business Milestones Timeline

2026 Outlook & Strategic Priorities